Warburg Pincus nears $7 billion deal for PANTHERx Rare pharmacy

Warburg Pincus is nearing a deal to acquire PANTHERx Rare for more than $7 billion including debt, according to people familiar with the matter, in what would be one of the largest leveraged buyouts in the specialty pharmacy sector this year.

The private equity firm is partnering with Abu Dhabi Investment Authority on the acquisition, the Wall Street Journal reported Friday. A deal could come together soon, the people said, though nothing is finalized and the timing could still slip.

Pittsburgh-based PANTHERx specializes in distributing medicines and providing patient support services for rare and orphan diseases. The company is owned by an investor group that includes General Atlantic, Nautic Partners and The Vistria Group, which acquired it from Centene Corp. in 2022 for an undisclosed sum. Centene had bought PANTHERx in 2020 before divesting it as part of a broader push to focus on its core health insurance operations.

Warburg, which manages more than $100 billion in assets, already holds several healthcare investments including cancer research provider START Center for Cancer Research and drug manufacturer Simtra BioPharma Solutions. The potential acquisition comes as private equity firms seek to increase deal activity after a prolonged slowdown, with a backlog of portfolio companies awaiting exits.

The deal shows sustained investor appetite for rare-disease drug distribution, a niche that benefits from high barriers to entry and stable reimbursement streams. Specialty pharmacies like PANTHERx handle complex, high-cost medications that require specialized handling and patient monitoring — services that generate recurring revenue largely independent of drug pricing cycles.

The transaction would also mark a significant exit for General Atlantic and its co-investors, who acquired PANTHERx from Centene four years ago. For Warburg, the deal would add a high-margin distribution platform to its healthcare portfolio, complementing its existing investments in drug manufacturing and clinical research.

This article is for informational purposes only and does not constitute investment advice.